Sharron McCulloch
Vice President,
Clinical Operations
Sharron McCulloch became the Vice President of Clinical Operations at Britecyte in January 2024. Prior to joining Britecyte, Sharron spent 20 years at Osiris Therapeutics, a leader in the regenerative medicine space. During her tenure at Osiris Therapeutics, Sharron held numerous leadership positions most recently serving as the Senior Director of Medical & Clinical Affairs, delivering strategic planning and oversight for scientific and clinical medical affairs programs alongside cross-functional teams. In this role, she had direct involvement with several studies resulting in peer-reviewed publications describing the clinical and commercial applications of tissue-based products across various indications, providing critical evidence for obtaining market access and reimbursement. Sharron was instrumental in helping to develop and provide oversight in all phases of the multi-center clinical trials. Earlier in her career, she played a key role in the development and launch of Osteocel®, the world’s first bone allograft containing native mesenchymal stem cells. In 2019, Osiris was acquired by Smith+Nephew, a global medical technology business, where Sharron further expanded her clinical experience as the Director of US Global Clinical Operations for medical device studies.
Sharron earned a BS degree in Biology from Gettysburg College and a MS degree in Biotechnology from the Johns Hopkins University. Additionally, she is a Certified Clinical Research Professional (CCRP) by the Society of Clinical Research Associates (SOCRA).